期刊
MOLECULAR PHARMACEUTICS
卷 12, 期 9, 页码 3202-3213出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.molpharmaceut.5b00153
关键词
albumin; nanoparticle; modification; gene delivery; human mesenchymal stem cell
资金
- German Bundesministerium fur Bildung and Forschung (BMBF) [13N11539, 13N11540, 13N11541]
The development of nonviral gene delivery systems is a great challenge to enable safe gene therapy. In this study, ligand-modified nanopartides based on human serum albumin (HSA) were developed and optimized for an efficient gene therapy. Different glutaraldehyde cross-linking degrees were investigated to optimize the HSA nanopartides for gene delivery. The peptide sequence arginine-glycine-aspartate (RGD) and the HIV-1 transactivator of transduction sequence (Tat) are well-known as promising targeting ligands. Plasmid DNA loaded HSA nanopartides were covalently modified on their surface with these different ligands. The transfection potential of the obtained plasmid DNA loaded RGD-and Tat-modified nanopartides was investigated in vitro, and optimal incubation conditions for these preparations were studied. It turned out that Tat-modified HSA nanopartides with the lowest cross-linking degree of 20% showed the highest transfection potential. Taken together, ligand-functionalized represent promising tools for efficient and safe gene therapy. HSA nanopartides
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据